ACE-031
ActRIIB-Fc / Soluble activin receptor IIB
- Molecular form
- ActRIIB–Fc fusion protein
ActRIIB–Fc fusion protein
Open the sources to check how the studies were done and what they can support.
An experimental activin-receptor fusion protein studied in Duchenne muscular dystrophy.
- Family
- Ligand-trapping fusion protein
- Research target
- Myostatin and related activin ligands
- Molecular form
- ActRIIB–Fc fusion protein
What to know about the research
The randomized study was discontinued because of non-muscle adverse events. Changes in muscle-related measures cannot be interpreted without that safety outcome.
Check the exact compound
ACE-031 is a receptor fusion protein, not follistatin or a selective short myostatin peptide.
What supports this entry?
3 of 3 summary statements linked to checked source passages.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
Check the overview statementSource checked
An experimental activin-receptor fusion protein studied in Duchenne muscular dystrophy.
Abstract: Introduction, Methods, Results and Conclusion
- Selected primary-source passages checked with AI assistance. Scope cautions are editorial interpretations; this is not a complete literature review.
Check the evidence limitationSource checked
The randomized study was discontinued because of non-muscle adverse events. Changes in muscle-related measures cannot be interpreted without that safety outcome.
Abstract: Introduction, Methods, Results and Conclusion
- Selected primary-source passages checked with AI assistance. Scope cautions are editorial interpretations; this is not a complete literature review.
Check the identity statementSource checked
ACE-031 is a receptor fusion protein, not follistatin or a selective short myostatin peptide.
Abstract: Introduction, Methods, Results and Conclusion
- Selected primary-source passages checked with AI assistance. Scope cautions are editorial interpretations; this is not a complete literature review.
Inside the selected studies
Randomized, double-blind, placebo-controlled trial
ACE-031 activin-receptor fusion protein
- Who or what was studied
- Ambulatory boys with Duchenne muscular dystrophy
- Sample size
- Not established. Not established from the checked abstract; full methods require review.
- Compared with
- Placebo
- Duration
- Not established. Not established from the checked abstract; full methods require review.
- Safety was the primary objective; nosebleeds and telangiectasias contributed to stopping the trial.
- The walking-distance trend was not statistically significant.
- Selected study only; source mapping is not independent study-quality appraisal.
- The finding applies to this population, preparation and study design.